Summary by Moomoo AI
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 2,465 shares of common stock on February 28, 2024, according to a recent filing. The shares, valued at an aggregate market value of $26,129, were acquired by Watanabe on February 27, 2024, through the vesting of restricted stock directly from Arcutis Biotherapeutics. This transaction follows a period where no other sales were reported by Watanabe in the past three months.